Black Diamond Therapeutics, Inc. - 8-K Filing

Black Diamond Therapeutics reports Q3 2026 results and positive updated silevertinib Phase 2 data with FDA feedback supporting accelerated approval path. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)

SEC EDGAR · November 10, 2026, 11:28 UTC

Tickers: $BDTX

Read the full article at SEC EDGAR

More Regulatory news

SusGlobal Energy Corp. - 10-Q Filing SEC EDGAR · November 12, 2026, 14:42 UTC
Ideal Power Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:25 UTC
DIGI INTERNATIONAL INC - 8-K Filing SEC EDGAR · November 12, 2026, 14:23 UTC
ZeroStack Corp. - 8-K Filing SEC EDGAR · November 12, 2026, 14:22 UTC
Sound Point Meridian Capital, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:22 UTC
Boost Run Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:20 UTC
INTERFACE INC - 8-K Filing SEC EDGAR · November 12, 2026, 14:20 UTC
Neonode Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 14:20 UTC
Virtuix Holdings Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:20 UTC
Neonode Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:18 UTC